Volume | 742,405 |
|
|||||
News | - | ||||||
Day High | 0.524 | Low High |
|||||
Day Low | 0.48 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioVie Inc | BIVI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.50 | 0.48 | 0.524 | 0.4918 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,359 | 742,405 | $ 0.5025583 | $ 373,102 | - | 0.445 - 8.69 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:26:49 | 100 | $ 0.5057 | USD |
BioVie Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
20.33M | 39.87M | - | 0 | -50.26M | -1.26 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioVie News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIVI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.4975 | 0.524 | 0.4521 | 0.4853032 | 733,778 | 0.0082 | 1.65% |
1 Month | 0.545 | 0.561 | 0.445 | 0.4992196 | 908,943 | -0.0393 | -7.21% |
3 Months | 1.04 | 3.31 | 0.445 | 1.41 | 2,768,000 | -0.5343 | -51.38% |
6 Months | 3.54 | 5.82 | 0.445 | 1.70 | 1,705,609 | -3.03 | -85.71% |
1 Year | 7.83 | 8.69 | 0.445 | 2.05 | 962,222 | -7.32 | -93.54% |
3 Years | 18.75 | 23.86 | 0.445 | 3.82 | 507,601 | -18.24 | -97.30% |
5 Years | 10.50 | 46.0977 | 0.445 | 4.32 | 434,855 | -9.99 | -95.18% |
BioVie Description
BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |